Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 6/20 | 0.35 |
| ▸ | PRKDC | P78527 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137806 | 0.93 | ATR (0.45) | ATRACVR1ATMPRKDC | |
| SCHEMBL13137808 | 0.90 | ACVR1 (0.42) | ATRACVR1ATMPRKDC | |
| SCHEMBL17826570 | 0.85 | ATR (0.54) | ATRATMPRKDC | |
| SCHEMBL16489013 | 0.85 | ATR (0.33) | ATR | |
| SCHEMBL13138162 | 0.79 | ATR (0.61) | ATRACVR1ATMPRKDC | |
| SCHEMBL16491601 | 0.79 | ATR (0.59) | ATRACVR1ATMPRKDC | |
| SCHEMBL13138349 | 0.79 | ATR (0.60) | ATRACVR1ATMPRKDC | |
| SCHEMBL21572084 | 0.79 | ATR (0.54) | ATRATMPRKDC | |
| SCHEMBL16489014 | 0.78 | ATR (0.33) | ATR | |
| SCHEMBL21572085 | 0.78 | ATR (0.62) | ATRACVR1ATMPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222318-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885ACVR1 765/4885ATM 39/4885 |
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885ACVR1 765/4885ATM 39/4885 |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885ACVR1 765/4885ATM 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.